Contrasting Aditxt (ADTX) & Its Competitors

Aditxt (NASDAQ:ADTX) is one of 248 publicly-traded companies in the “MED – DRUGS” industry, but how does it compare to its competitors? We will compare Aditxt to related companies based on the strength of its dividends, analyst recommendations, earnings, risk, profitability, institutional ownership and valuation.

Risk & Volatility

Aditxt has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, Aditxt’s competitors have a beta of 1.28, suggesting that their average share price is 28% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Aditxt and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1	0	0	0	1.00
Aditxt Competitors	1923	3657	9671	390	2.55

As a group, “MED – DRUGS” companies have a potential upside of 74.55%. Given Aditxt’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Aditxt has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Aditxt and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aditxt	$130,000.00	-$34.45 million	0.00
Aditxt Competitors	$30.37 billion	$56.85 million	-3.73

Aditxt’s competitors have higher revenue and earnings than Aditxt. Aditxt is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

15.5% of Aditxt shares are held by institutional investors. Comparatively, 43.8% of shares of all “MED – DRUGS” companies are held by institutional investors. 0.0% of Aditxt shares are held by insiders. Comparatively, 13.7% of shares of all “MED – DRUGS” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Aditxt and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aditxt	-206,431.38%	-316.98%	-80.88%
Aditxt Competitors	-19,397.67%	-91.62%	-16.27%

Summary

Aditxt competitors beat Aditxt on 11 of the 13 factors compared.

Aditxt Company Profile

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.